PRIMARY STUDY
Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review
Key Findings: This review of the current literature on the role of the endocannabinoid system (ECS) and the use of cannabidiol (CBD) in the treatment of patients with Autism spectrum disorder (ASD) concludes that: CBD in pure form is useful in treating symptoms and comorbidities of ASD, can regulate several different neurotransmitters, and can modulate endogenous ligands, enzymes, and membrane transporters of the ECS.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Brazil
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Isolate
Chemotype: Chemotype III
Ligands Studied: Dopamine, GABA, Glutamate, Serotonin
Citation: de Camargo RW, et al. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review. Pharmacol Biochem Behav. 2022; 221:173492. doi: 10.1016/j.pbb.2022.173492
Authors: de Camargo RW, de Novais Júnior LR, da Silva LM, Meneguzzo V, Daros GC, da Silva MG, de Bitencourt RM
